<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621348</url>
  </required_header>
  <id_info>
    <org_study_id>RL-1</org_study_id>
    <nct_id>NCT00621348</nct_id>
  </id_info>
  <brief_title>Maintenance Intravenous Fluids in Children</brief_title>
  <official_title>A RCT to Evaluate the Effect of Normal Saline in 5% Dextrose at Maintenance Rate, N/5 Saline in 5% Dextrose at 2/3 Maintenance Rate and N/5 Saline in 5% Dextrose at Maintenance Rate on Incidence of Hyponatremia in Hospitalized Children.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, New Delhi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyponatraemia arises in between 20% and 45% of sick hospitalized children. An important
      reason for this high incidence could be use of hypotonic fluids in sick children for
      maintenance fluid therapy. There are no randomized controlled trials to evaluate the effect
      of various types of intravenous fluids on the incidence of hyponatremia in sick hospitalized
      children.

      Hypothesis: Use of normal saline in 5% dextrose or reduced (2/3) volume of N/5 saline in 5%
      dextrose reduces incidence of hyponatremia (serum sodium 130 mmol/L) by two-thirds when
      compared to N/5 saline in 5% dextrose at standard maintenance rate in hospitalized children
      receiving intravenous maintenance fluids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyponatraemia arises in between 20% and 45% of sick hospitalized children. An important
      reason for this high incidence could be use of hypotonic fluids in sick children for
      maintenance fluid therapy. There are no randomized controlled trials to evaluate the effect
      of various types of intravenous fluids on the incidence of hyponatremia in sick hospitalized
      children. We therefore plan to conduct a randomized controlled trial to evaluate the effect
      of normal saline in 5% dextrose at standard maintenance rate, reduced volume (2/3 maintenance
      rate) of N/5 saline in 5% dextrose and N/5 saline in 5% dextrose at standard maintenance rate
      on the incidence of hyponatremia in hospitalized children, aged 3 months- 12 years. To
      determine serial plasma vasopressin levels in hospitalized children at baseline, 24 hours and
      48 hours of intravenous fluid therapy and compare the values in the three fluid regimens.

      Study design: Randomized controlled trial. Hospitalized children who fulfill inclusion
      criteria and not having any of the exclusion criteria will be considered for the enrolment
      after written informed consent. Venous blood samples will be taken at enrollment for
      estimation of serum sodium, potassium, chloride, bicarbonate, blood gas, blood sugar, blood
      urea, serum creatinine, and plasma osmolality. A sample for estimation of plasma vasopressin
      will be collected at baseline. After randomization into three groups, one group of children
      will receive N/5 saline in 5% dextrose at standard maintenance rate (100 ml/kg for the first
      10 kg of body weight, 50 ml/kg for the next 10 kg, and 20 ml/kg for body weight exceeding 20
      kg).The second group of children will receive N/5 saline in 5% dextrose at 2/3 maintenance
      rate. The third group will receive dextrose normal saline at standard maintenance rate. Serum
      Na+, K+ and urine Na+, K+ will be estimated every 12 hourly till the patient is on
      intravenous fluid therapy and 12 hrs after stopping exclusive intravenous maintenance fluids.
      Serum and urine osmolality will be estimated every 24 hrs by an osmometer. Plasma vasopressin
      will be estimated in children in the 3 groups at 24, and 48 hours of intravenous fluid
      therapy.

      Children will be weighed every 24 hours. The fluid balance, sodium balance, free water
      clearance will be calculated in a subset of children.

      The study measurements will be carried out only till the time the child is on exclusive
      intravenous maintenance fluid therapy or 72 hrs of starting the intravenous fluid therapy.
      The decision to decrease/ stop intravenous fluid therapy will be left to the treating unit.

      The primary outcome measure will be incidence of hyponatremia (defined as serum Na+ less than
      130 mmol/L).

      The secondary outcomes studied will be Plasma vasopressin levels at 24 hr and 48 hours and
      incidence of hypernatremia.

      Sample size: Based on literature review, the incidence of hyponatremia with standard
      intravenous fluid therapy is approximately 30%. Sample of 72 patients will be needed in each
      group to demonstrate the decrease in incidence of hyponatremia to 10%, with a beta of 0.2
      (Power 80%) and alpha error of 0.05.

      Analysis: The data will be analyzed using STATA software. The outcomes (primary and
      secondary) in the 3 groups will be compared. For continuous variables, t test or Wilcoxon
      rank-sum test will be used to determine statistical significance. For categorical variables,
      chi square test will be used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Hyponatremia (Defined as Serum Sodium Less Than 130 mmol/L)</measure>
    <time_frame>72 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hypernatremia (Serum Sodium &gt;150 mmol/L)</measure>
    <time_frame>72 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Symptomatic Hyponatremia</measure>
    <time_frame>72 hrs</time_frame>
    <description>Defined as Hyponatremia (serum sodium &lt; 130 mnol/L)and presence of symptoms attributed to hyponatremia such as altered sensorium, seizure, headache, and vomiting which can not be explained otherwise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Symptomatic Hypernatremia</measure>
    <time_frame>72 hrs</time_frame>
    <description>Symptomatic hypernatremia is defined as serum sodium &gt; 150 mmol/L and the presence of symptoms like altered sensorium, seizure, headache and vomiting not explained otherwise.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Isotonic fluid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal saline in 5% dextrose at standard maintenance rate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluid restriction group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypotonic fluid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N/5 saline in 5% dextrose at standard maintenance rate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic fluid</intervention_name>
    <description>0.9% saline with 5% dextrose at standard maintenance rate</description>
    <arm_group_label>Isotonic fluid group</arm_group_label>
    <other_name>Dextrose normal saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypotonic fluid</intervention_name>
    <description>Reduced volume (two thirds of standard maintenance rate) of N/5 saline in 5% dextrose</description>
    <arm_group_label>Fluid restriction group</arm_group_label>
    <other_name>Hypotonic fluid,</other_name>
    <other_name>0.2 % saline in 5 % dextrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypotonic fluid</intervention_name>
    <description>N/5 saline in 5% dextrose at standard maintenance rate</description>
    <arm_group_label>Hypotonic fluid group</arm_group_label>
    <other_name>0.2 % saline in 5% dextrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All children (3 months to 12 years) who are admitted to pediatric ward or pediatric
             ICU, who require exclusive intravenous maintenance fluid therapy for at least 24 hours
             will be eligible for the study

        Exclusion Criteria:

          -  Children with illness that have primary fluid and electrolyte imbalance such as:

               -  Shock: Defined as acute circulatory failure resulting in decreased tissue
                  perfusion and manifesting as altered sensorium, hypothermia (&lt;35oC), tachycardia,
                  prolonged capillary filling time (&gt;3 seconds), hypotension (BP &lt; 5th percentile
                  for age), oliguria (&lt;0.5 ml/kg/hr), hypoxemia, hyperlactatemia, requirement of
                  fluid bolus and/ or vasopressors.

               -  Diarrhea and Dehydration: Children presenting with diarrhea and features of
                  dehydration: lethargy, irritability and altered sensorium, thirst, decreased
                  urine output, sunken eyes &amp; dry mucous membranes, loss of skin elasticity.;
                  children with ongoing diarrhea will be excluded even if there is no dehydration.

               -  Fluid Overload: Cirrhosis, Congestive heart failure, Acute and Chronic renal
                  failure, Nephrotic syndrome.

          -  Abnormal serum sodium or Hyperglycemia at Presentation:

               -  Hyponatremia : serum sodium &lt; 130 mmol/L.

               -  Hypernatremia : serum sodium &gt;150 mmol/L.

               -  Hyperglycemia: blood glucose &gt; 180 mg/ dl.

          -  Severe Protein Energy Malnutrition: Defined as grade III (50-59% of expected weight
             for age) and grade IV (less than 50% of expected weight for age) as per IAP
             classification.

          -  Child who is receiving drugs which cause abnormality in serum sodium such as
             diuretics, vasopressin, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rakesh Lodha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Kannan L, Lodha R, Vivekanandhan S, Bagga A, Kabra SK, Kabra M. Intravenous fluid regimen and hyponatraemia among children: a randomized controlled trial. Pediatr Nephrol. 2010 Nov;25(11):2303-9. doi: 10.1007/s00467-010-1600-4. Epub 2010 Jul 29.</citation>
    <PMID>20668885</PMID>
  </results_reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2008</study_first_submitted>
  <study_first_submitted_qc>February 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <results_first_submitted>July 12, 2011</results_first_submitted>
  <results_first_submitted_qc>July 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2011</results_first_posted>
  <last_update_submitted>August 8, 2011</last_update_submitted>
  <last_update_submitted_qc>August 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Rakesh Lodha</name_title>
    <organization>All India Institute of Medical Sciences</organization>
  </responsible_party>
  <keyword>maintenance fluids</keyword>
  <keyword>hyponatremia</keyword>
  <keyword>vasopressin</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment: September 2006 to April 2008 Analysis: May and June 2008 Pediatric ward and Pediatric intensive care unit in a tertiary care referral hospital in North India</recruitment_details>
      <pre_assignment_details>Patients were stratified based on their age in to three groups (age 3 months to 1 year, 1-5 years, 6-12 years) and stratified randomization was used.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dextrose Normal Saline</title>
          <description>Normal saline in 5% dextrose at standard maintenance rate</description>
        </group>
        <group group_id="P2">
          <title>Fluid Restriction Group</title>
          <description>Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose</description>
        </group>
        <group group_id="P3">
          <title>Hypotonic Saline</title>
          <description>N/5 saline in 5% dextrose at standard maintenance rate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dextrose Normal Saline</title>
          <description>Normal saline in 5% dextrose at standard maintenance rate</description>
        </group>
        <group group_id="B2">
          <title>Fluid Restriction Group</title>
          <description>Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose</description>
        </group>
        <group group_id="B3">
          <title>Hypotonic Saline</title>
          <description>N/5 saline in 5% dextrose at standard maintenance rate</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="56"/>
            <count group_id="B4" value="167"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" spread="0.44"/>
                    <measurement group_id="B2" value="3" spread="0.36"/>
                    <measurement group_id="B3" value="4" spread="0.28"/>
                    <measurement group_id="B4" value="3.33" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Hyponatremia (Defined as Serum Sodium Less Than 130 mmol/L)</title>
        <time_frame>72 hrs</time_frame>
        <population>432 patients were eligible. 203 patients were excluded and 62 patients declined consent . Out of 167 patients, 58 patients were randomized to Arm 1, 53 to arm 2 and 56 to arm 3.Intention to treat analysis was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Dextrose Normal Saline</title>
            <description>Normal saline in 5% dextrose at standard maintenance rate</description>
          </group>
          <group group_id="O2">
            <title>Fluid Restriction Group</title>
            <description>Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose</description>
          </group>
          <group group_id="O3">
            <title>Hypotonic Saline</title>
            <description>N/5 saline in 5% dextrose at standard maintenance rate</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hyponatremia (Defined as Serum Sodium Less Than 130 mmol/L)</title>
          <population>432 patients were eligible. 203 patients were excluded and 62 patients declined consent . Out of 167 patients, 58 patients were randomized to Arm 1, 53 to arm 2 and 56 to arm 3.Intention to treat analysis was used.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The incidence of hospital-acquired hyponatremia with current standard intravenous fluid therapy was approximately 30%. Sample of 72 patients would be needed in each group to demonstrate the decrease in incidence of hyponatremia (defined as plasma sodium&lt; 130 mEq/L) to 10%, with a power of 80 percent and alpha error of 0.05. In view of short study period and feasibility it was planned a priori to enroll at least 50 patients in each treatment limb.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence analysis</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>p value was adjusted for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>The risk ratio is for Group A compared with Group C.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hypernatremia (Serum Sodium &gt;150 mmol/L)</title>
        <time_frame>72 hrs</time_frame>
        <population>Intention To Treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Dextrose Normal Saline</title>
            <description>Normal saline in 5% dextrose at standard maintenance rate</description>
          </group>
          <group group_id="O2">
            <title>Fluid Restriction Group</title>
            <description>Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose</description>
          </group>
          <group group_id="O3">
            <title>Hypotonic Saline</title>
            <description>N/5 saline in 5% dextrose at standard maintenance rate</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypernatremia (Serum Sodium &gt;150 mmol/L)</title>
          <population>Intention To Treat analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Symptomatic Hyponatremia</title>
        <description>Defined as Hyponatremia (serum sodium &lt; 130 mnol/L)and presence of symptoms attributed to hyponatremia such as altered sensorium, seizure, headache, and vomiting which can not be explained otherwise.</description>
        <time_frame>72 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dextrose Normal Saline</title>
            <description>Normal saline in 5% dextrose at standard maintenance rate</description>
          </group>
          <group group_id="O2">
            <title>Fluid Restriction Group</title>
            <description>Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose</description>
          </group>
          <group group_id="O3">
            <title>Hypotonic Saline</title>
            <description>N/5 saline in 5% dextrose at standard maintenance rate</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Symptomatic Hyponatremia</title>
          <description>Defined as Hyponatremia (serum sodium &lt; 130 mnol/L)and presence of symptoms attributed to hyponatremia such as altered sensorium, seizure, headache, and vomiting which can not be explained otherwise.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Symptomatic Hypernatremia</title>
        <description>Symptomatic hypernatremia is defined as serum sodium &gt; 150 mmol/L and the presence of symptoms like altered sensorium, seizure, headache and vomiting not explained otherwise.</description>
        <time_frame>72 hrs</time_frame>
        <population>Intention to Treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Dextrose Normal Saline</title>
            <description>Normal saline in 5% dextrose at standard maintenance rate</description>
          </group>
          <group group_id="O2">
            <title>Fluid Restriction Group</title>
            <description>Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose</description>
          </group>
          <group group_id="O3">
            <title>Hypotonic Saline</title>
            <description>N/5 saline in 5% dextrose at standard maintenance rate</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Symptomatic Hypernatremia</title>
          <description>Symptomatic hypernatremia is defined as serum sodium &gt; 150 mmol/L and the presence of symptoms like altered sensorium, seizure, headache and vomiting not explained otherwise.</description>
          <population>Intention to Treat analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dextrose Normal Saline</title>
          <description>Normal saline in 5% dextrose at standard maintenance rate</description>
        </group>
        <group group_id="E2">
          <title>Fluid Restriction Group</title>
          <description>Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose</description>
        </group>
        <group group_id="E3">
          <title>Hypotonic Saline</title>
          <description>N/5 saline in 5% dextrose at standard maintenance rate</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Death or symptomatic hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rakesh Lodha</name_or_title>
      <organization>AIIMS</organization>
      <phone>91 11 26593621</phone>
      <email>rakesh_lodha@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

